Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: Dave Walp who wrote (2510)	6/4/1998 9:07:00 PM
From: art slott	Respond to of 3725

It sure helped Adac, up 3+. And it will be very good for Imat since they now make $ selling Pet scans. Millions of people on Medicare. I'm sure that their is pent up demand to. go2net.newsalert.com Art

To: Dave Walp who wrote (2510)	6/8/1998 12:16:00 AM
From: Steven Durrington	Read Replies (1) \| Respond to of 3725

Positron Emission Tomography (PET) is what IMAT is now involved in. So yes, this news release does has relevance. SPECT is a type of conventional Nuclear Medicine Scan. I found it interesting that PET and SPECT are being accorded the same charges. PET is a more expensive machine to purchase, and requires an on-site cyclotron to produce isotopes of short half life. The isotopes for SPECT can come from a remote site via a "cow" (generator). PET is more time consuming and labor intensive than conventional Nuc Med. This all adds up to PET being more expensive than SPECT. But, I guess they had to find a starting figure from somewhere, and for the lay person, the 2 procedures sound kind of similar. Still, I think that this charge should be revised upwards in the future. Regards, Durro